REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets

— Precision oncology programs and innovation engines to be merged —

REDWOOD CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–REVOLUTION
Medicines, Inc.
and Warp Drive Bio, Inc. announced
today that REVOLUTION Medicines is acquiring Warp Drive Bio. The
acquisition will combine the companies’ complementary drug discovery
technologies and precision oncology programs directed toward frontier
oncology targets – elusive drivers of notorious cancer-promoting
pathways. The deal, which is expected to close by the end of this month
subject to customary closing conditions, involves issuance of REVOLUTION
Medicines stock to stockholders of Warp Drive Bio.

The merged R&D portfolio represents a rich pipeline of near- and
long-term development opportunities for our R&D team to advance in
support of our continuing commitment to translate frontier oncology
targets on behalf of cancer patients,” said Mark A. Goldsmith, M.D.,
Ph.D., president and chief executive officer of REVOLUTION Medicines.
We appreciate the groundbreaking research by Warp Drive Bio scientists
that inspired this deal. The synergistic combination of capabilities and
assets will deepen our ability to target cancer drivers precisely and
comprehensively and will accelerate our trajectory as a leading oncology
company.”

This strategic transaction brings together two biotechnology companies
that are both grounded in the molecules and mechanisms of nature to
discover first- and/or best-in-class drugs. REVOLUTION Medicines deploys
deep biological pathway discovery and advanced chemistry, including its
REVBLOCKS™ modular platform, to discover and develop small and more
complex “beyond rule of 5” molecules to defeat frontier targets that
drive cancer. Its lead program is directed to the enzyme SHP2, a key
regulator of growth signaling by select oncogenic mutant proteins in the
RAS growth signaling pathway. The company’s selective SHP2 inhibitor
RMC-4630 is currently in a Phase 1 clinical trial and is the centerpiece
of a global collaboration with Sanofi on SHP2. Additional programs in
the preclinical pipeline target other key cancer-promoting pathways.

Warp Drive Bio developed a highly innovative drug modality (SMART™)
based on the molecular design and optimization of compounds to engage
surfaces on disease-causing proteins that were previously viewed as
undruggable. Inhibitors created using this technology exploit unique
molecular contacts that have not been possible with traditional small
molecules, which enables highly differentiated modes of action. For
example, unlike other compounds that have been described, inhibitors of
KRAS-G12C derived by this approach uniquely antagonize the activated
(GTP-bound) form of this prominent driver of cancer. This platform is
highly compatible with the strengths of REVOLUTION Medicines in
exploiting natural product macrocycles as chemical leads, and the
KRAS-targeted programs are complementary to its existing precision
oncology pipeline.

I’m proud of the outstanding work by our team that has delivered
promising platform advances and product opportunities,” said Laurence
Reid, Ph.D., president and chief executive officer of Warp Drive Bio.
Our board of directors is confident that integrating the two companies’
portfolios is the right path to create a strong, diversified and
synergistic oncology product pipeline. REVOLUTION Medicines is an
excellent organization for maximizing impact for cancer patients from
the merged portfolio and creating value for investors.”

REVOLUTION Medicines will maintain a research site in Cambridge during a
transition period. Warp Drive Bio’s discovery collaborations with
GlaxoSmithKline (oncology) and Roche (antibiotics) will continue while
REVOLUTION Medicines determines its business strategy for the genome
mining platform.

About REVOLUTION Medicines

The mission of REVOLUTION Medicines is to discover and develop new drugs
directed toward frontier oncology targets for cancer patients. Frontier
targets include proteins that drive the growth and survival of cancer
but carry atypical structural or regulatory features requiring
unconventional drug discovery strategies. The company brings together
deep talent in cancer biology and small molecule drug discovery
supported by advanced chemical synthesis, computational and assay
technologies to master these targets. Seasoned translational and
development scientists help to fulfill the company’s commitment to
precision oncology.

Headquartered in Redwood City, Calif. at the intersection of Silicon
Valley and the birthplace of biotechnology, REVOLUTION Medicines is a
private company financed by top-tier investors.

REVOLUTION Medicines: Translating frontier oncology targets to
outsmart cancer

Relevant links:

www.revolutionmedicines.com

www.warpdrivebio.com

Contacts

1AB
Media Contact:
Katie
Engleman, 910-632-0405
katie@1abmedia.com

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.